Literature DB >> 21359860

A case report of a 33-year chronic phase survivor of chronic myeloid leukemia.

Ou Ji1, Qun Shen, Ya-Cheng Zhang, Jian-Min Ji, Guang-Rong Zhu, Lin Lin, Xiang-Tu Kong, Wen Xia, Peng-Jun Jiang.   

Abstract

Here, we report a Philadelphia chromosome-positive chronic myeloid leukemia case with the longest chronic phase and overall survival to our knowledge ever reported in the medical literature. During the 33-year chronic phase, he was asymptomatic without any treatment and had normal blood cell values. BCR-ABL silencing might be referred to the uncommon long-term survivor.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21359860     DOI： 10.1007/s12032-011-9874-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  10 in total

Review 1.  Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?

Authors:  Tariq I Mughal; John M Goldman
Journal:  Front Biosci       Date:  2006-01-01

2.  Suppression of bcr-abl mRNA by chemically modified siRNA.

Authors:  Satoshi Murao; Irmina Diala; Masayuki Fujii
Journal:  Nucleic Acids Symp Ser (Oxf)       Date:  2008

3.  Uncommon long-term survival in a patient with chronic myeloid leukemia.

Authors:  Fabio Stagno; Paolo Vigneri; Fabio Stagno; Paolo Vigneri; Vittorio Del Fabro; Stefania Stella; Salvatore Berretta; Michele Massimino; Elena Tirrò; Angelo Messina; Francesco Di Raimondo
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

4.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.

Authors:  D Cortez; G Reuther; A M Pendergast
Journal:  Oncogene       Date:  1997-11-06       Impact factor: 9.867

5.  Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.

Authors:  J C Chomel; F Brizard; A Veinstein; J Rivet; A Sadoun; A Kitzis; F Guilhot; A Brizard
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

6.  Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.

Authors:  Ali Zaree Mahmodabady; Hamid Reza Javadi; Mehdi Kamali; Ali Najafi; Zahra Hojati
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

7.  Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.

Authors:  J Rangatia; D Bonnet
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

8.  BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.

Authors:  A Bedi; B A Zehnbauer; M I Collector; J P Barber; M S Zicha; S J Sharkis; R J Jones
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

9.  Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.

Authors:  D P Busuttil
Journal:  Int J Lab Hematol       Date:  2008-02       Impact factor: 2.877

10.  Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.

Authors:  M Koldehoff; N K Steckel; D W Beelen; A H Elmaagacli
Journal:  Clin Exp Med       Date:  2007-07-04       Impact factor: 3.984
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.